CMV retinopathy in the antiretroviral therapy era: Prevention, diagnosis, and management

Current Infectious Disease Reports

Volumn 14, Issue 4, 2012, Pages 435-444

  Barrett, Lisa ^a   Walmsley, Sharon ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Antiretroviral therapy; CMV; Diagnosis; HIV; Management; Retinitis

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR; VALGANCICLOVIR;

ANTIBIOTIC RESISTANCE; ARTICLE; CYTOMEGALOVIRUS RETINITIS; CYTOMEGALOVIRUS RETINOPATHY; DISEASE ASSOCIATION; DRUG DOSAGE FORM COMPARISON; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOTHERAPY; INCIDENCE; INFECTION PREVENTION; MAINTENANCE CHEMOTHERAPY; MORTALITY; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; RETINOPATHY; SEROLOGY; SEROPREVALENCE; VIRUS DETECTION; VIRUS INFECTIVITY; VIRUS LATENCY; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 84865634042     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0269-1     Document Type: Article

References (68)

1. Jabs DA, Van Natta ML, Kempen JH, Reed Pavan P, Lim JI, Murphy RL, Hubbard LD. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol. 2002;133:48-61. Once of the largest published prospective cohorts of HAART treated HIV patients with CMV retinitis. (Pubitemid 34076503)
2. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. N Engl J Med. 1992;326:213-20.
3. Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD. Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment. Ophthalmology. 2007;114:780-6.
4. Pertel P, Hirschtick R, Phair J, Chmiel J, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr. 1992;5:1069-74.
5. Rao NA, Zhang J, Ishimoto S. Role of retinal vascular endothelial cells in development of CMV retinitis. Trans Am Ophthalmol Soc. 1998;96:111-23.
6. Freeman WR, Henderly DE, Lipson BK, Rao NA, Levine AM. Retinopathy before the diagnosis of AIDS. Ann Ophthalmol. 1989;21:468-74.
7. Holland GN, Vaudaux JD, Jeng SM, Yu F, Goldenberg DT, Folz IC, Cumberland WG, McCannel CA, Helm CJ, Hardy WD. Characteristics of untreated AIDS-related cytomegalovirus retinitis. I. Findings before the era of highly active antiretroviral therapy (1988 to 1994). Am J Ophthalmol. 2008;145:5-11.
8. Arevalo JF, Mendoza AJ, Ferretti Y. Immune recovery uveitis in AIDS patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy in Venezuela. Retina. 2003;23: 495-502. (Pubitemid 37071963)
9. Karavellas MP, Lowder CY, Macdonald C, Avila Jr. CP, Freeman WR. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: A new syndrome. Arch Ophthalmol. 1998; 116:169-75.
10. Zegans ME, Walton RC, Holland GN, O'Donnell JJ, Jacobson MA, Margolis TP. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol. 1998; 125:292-300. (Pubitemid 28124356)
11. WrightME, Suzman DL, Csaky KG, Masur H, Polis MA, Robinson MR. Extensive retinal neovascularization as a late finding in human immunodeficiency virus-infected patients with immune recovery uveitis. Clin Infect Dis. 2003;36:1063-6. (Pubitemid 36513293)
12. Hecker M, Qiu D, Marquardt K, Bein G, Hackstein H. Continuous cytomegalovirus seroconversion in a large group of healthy blood donors. Vox Sang. 2004;86:41-4. (Pubitemid 38200454)
13. Spano LC, Gatti J, Nascimento JP, Leite JP. Prevalence of human cytomegalovirus infection in pregnant and non-pregnant women. J Infect. 2004;48:213-20. (Pubitemid 38380379)
14. Akinbami AA, Akanmu AS, Adeyemo TA, Wright KO, Dada MO, Dosunmu AO. Cytomegalovirus antibodies among healthy blood donors at Lagos University Teaching Hospital. SAMJ: South African Med J. 2009;99:528-30.
15. Jackson JB, Erice A, Englund JA, Edson JR, Balfour Jr. HH. Prevalence of cytomegalovirus antibody in hemophiliacs and homosexuals infected with human immunodeficiency virus type 1. Transfusion (Paris). 1988;28:187-9.
16. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Ophthalmology. 1994;101:1250-61.
17. Bloom JN, Palestine AG. The diagnosis of cytomegalovirus retinitis. Ann Intern Med. 1988;109:963-9. (Pubitemid 19046065)
18. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Am J Ophthalmol. 1997;124:141-57.
19. Holbrook JT, Jabs DA, Weinberg DV, Lewis RA, Davis MD, Friedberg D. Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. Arch Ophthalmol. 2003;121:99-107. (Pubitemid 36401774)
20. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis. 1992;166:1223-7.
21. Holland GN, Sison RF, Jatulis DE, Haslop MG, Sakamoto MJ, Wheeler NC. Survival of patients with the acquired immune deficiency syndrome after development of cytomegalovirus retinopathy. UCLA CMV Retinopathy Study Group. Ophthalmology. 1990;97:204-11. (Pubitemid 20051385)
22. Gross JG, Bozzette SA, Mathews WC, Spector SA, Abramson IS, McCutchan JA, Mendez T, Munguia D, Freeman WR. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 1990;97:681-6. (Pubitemid 20150725)
23. Bowen EF, Wilson P, Cope A, Sabin C, Griffiths P, Davey C, Johnson M, Emery V. Cytomegalovirus retinitis in AIDS patients: Influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS. 1996;10:1515-20. (Pubitemid 26370665)
24. Kempen JH, Jabs DA, Wilson LA, Dunn JP, West SK, Tonascia J. Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin Infect Dis. 2003; 37:1365-73. (Pubitemid 37433634)
25. Jabs DA, Holbrook JT, Van Natta ML, Clark R, Jacobson MA, Kempen JH, Murphy RL. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology. 2005;112:771-9. (Pubitemid 40631495)
26. Sugar EA, Jabs DA, Ahuja A, Thorne JE, Danis RP, Meinert CL. Incidence of Cytomegalovirus Retinitis in the Era of Highly Active Antiretroviral Therapy. Am J Ophthalmol 2012. Longer term data from a similar prospective cohort to that of reference 1, but includes some patients treated with more contemporary ART than previous studies.
27. Crum NF, Blade KA. Cytomegalovirus retinitis after immune reconstitution. AIDS Read. 2005;15:186-8. (Pubitemid 41057962)
28. Karavellas MP, Song M, Macdonald JC, Freeman WR. Long-Term posterior and anterior segment complications of immune recovery uveitis associated with cytomegalovirus retinitis. Am J Ophthalmol. 2000;130:57-64.
29. Nguyen QD, Kempen JH, Bolton SG, Dunn JP, Jabs DA. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol. 2000;129:634-9. (Pubitemid 30323730)
30. Karavellas MP, Azen SP, MacDonald JC, Shufelt CL, Lowder CY, Plummer DJ, Glasgow B, Torriani FJ, Freeman WR. Immune recovery vitritis and uveitis in AIDS: Clinical predictors, sequelae, and treatment outcomes. Retina. 2001;21:1-9. (Pubitemid 32151755)
31. Song MK, Azen SP, Buley A, Torriani F, Cheng L, Chaidhawangul S, Ozerdem U, Scholz B, Freeman WR. Effect of anticytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis. Am J Ophthalmol. 2003;136:696-702. (Pubitemid 37153185)
32. Sarrafizadeh R, Weinberg DV, Huang CF. An analysis of lesion size and location in newly diagnosed cytomegalovirus retinitis. Ophthalmology. 2002;109:119-25. (Pubitemid 34027434)
33. Hansen KK, Ricksten A, Hofmann B, Norrild B, Olofsson S, Mathiesen L. Detection of cytomegalovirus DNA in serum correlates with clinical cytomegalovirus retinitis in AIDS. J Infect Dis. 1994;170:1271-4. (Pubitemid 24328635)
34. Deayton JR, Prof Sabin CA, Johnson MA, Emery VC, Wilson P, Griffiths PD. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet. 2004; 363:2116-21. (Pubitemid 38844151)
35. Knox CM, Chandler D, Short GA, Margolis TP. Polymerase chain reaction-based assays of vitreous samples for the diagnosis of viral retinitis. Use in diagnostic dilemmas. Ophthalmology. 1998; 105:37-44.
36. Deayton JR, Wilson P, Sabin CA, Davey CC, Johnson MA, Emery VC, Griffiths PD. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS. 2000;14:1163-70. (Pubitemid 30420659)
37. Lilleri D, Piccinini G, Baldanti F, Seminari E, Galloni D, Gerna G. Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response. J Clin Virol. 2003;26:95-100. (Pubitemid 36183353)
38. Tay-Kearney ML, Enger C, Semba RD, Royal 3rd W, Dunn JP, Jabs DA. T cell subsets and cytomegalovirus retinitis in human immunodeficiency virus-infected patients. J Infect Dis. 1997; 176:790-4. (Pubitemid 27360553)
39. Bronke C, Westerlaken GH, Miedema F, Tesselaar K, van Baarle D. Progression to CMV end-organ disease in HIV-1-infected individuals despite abundance of highly differentiated CMV-specific CD8+ T-cells. Immunol Lett. 2005;97:215-24. (Pubitemid 40326954)
40. Goldberg DE, Smithen LM, Angelilli A, Freeman WR. HIVassociated retinopathy in the HAART era. Retina. 2005;25: 633-49.
41. Holland GN, Shuler JD. Progression rates of cytomegalovirus retinopathy in ganciclovir-Treated and untreated patients. Arch Ophthalmol. 1992;110:1435-42.
42. Jabs DA, Ahuja A, Van Natta M, Lyon A, Srivastava S, Gangaputra S. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: Five-year outcomes. Ophthalmology. 2010;117:2152-61. e1-2.
43. Jabs DA, Van Natta ML, Thorne JE, Weinberg DV, Meredith TA, Kuppermann BD, Sepkowitz K, Li HK. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology. 2004;111:2224-31. (Pubitemid 39585188)
44. Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD. Longitudinal study of the ocular complications of AIDS: 2. Ocular examination results at enrollment. Ophthalmology. 2007;114:787-93. (Pubitemid 46483694)
45. Thorne JE, Jabs DA, Kempen JH, Holbrook JT, Nichols C, Meinert CL. Causes of visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology. 2006;113:1441-5. (Pubitemid 44108167)
46. Lalonde RG, Boivin G, Deschenes J, Hodge WG, Hopkins JJ, Klein AH, Lindley JI, Phillips P, Shafran SD, Walmsley S. Canadian consensus guidelines for the management of cytomegalovirus disease in HIV/AIDS. Can J Infect Dis Med Micro. 2004;15:327-35. Good summary guidelines for managing CMV disease, including retinitis, in HIV patients. Several good diagrams and figures to summarize data. (Pubitemid 40065301)
47. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR. 2009;58:1-207.
48. Jabs DA. Cytomegalovirus retinitis and the acquired immunodeficiency syndrome-bench to bedside: LXVII Edward Jackson memorial lecture. Am J Ophthalmol 2011;151:198-216
49. Stewart MW. Optimal management of cytomegalovirus retinitis in patients with AIDS. Clin Ophthal. 2010;4:285-99.
50. Holbrook JT, Meinert CL, Van Natta ML, Davis M, Hubbard L, Jabs DA. Photographic measures of cytomegalovirus retinitis as surrogates for visual outcomes in treated patients. Arch Ophthalmol. 2001;119:554-63. (Pubitemid 32290064)
51. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Am J Ophthalmol. 2001;131:457-67.
52. Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P, Robinson CA, Stempien MJ. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002;346:1119-26. The first controlled trial to assess valganciclovir as induction therapy. (Pubitemid 34984602)
53. Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med. 1997;337:83-90. (Pubitemid 27284393)
54. Holbrook JT, Colvin R, van Natta ML, Thorne JE, Bardsley M, Jabs DA. Evaluation of the United States public health service guidelines for discontinuation of anticytomegalovirus therapy after immune recovery in patients with cytomegalovirus retinitis. Am J Ophthalmol. 2011;152:628-37 e1.
55. Walmsley SL, Raboud J, Angel JB, Mazzulli T, Shen S, Casciaro L, Young CD, Moussa G, Gough K, Rachlis A, Hopkins J. Longterm follow-up of a cohort of HIV-infected patients who discontinued maintenance therapy for cytomegalovirus retinitis. HIV Clin Trials. 2006;7:1-9. Comprehensive report to establish the safety of stopping maintenance therapy in CMV retinitis in HIV-infected patients with immune reconstitution.
56. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med. 2002;137:435-78.
57. Wohl DA, Kendall MA, Owens S, Holland G, Nokta M, Spector SA, Schrier R, Fiscus S, Davis M, Jacobson MA, Currier JS, Squires K, Alston-Smith B, Andersen J, Freeman WR, Higgins M, Torriani FJ. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. HIV Clin Trials. 2005;6:136-46. (Pubitemid 41341728)
58. Marx JL, Kapusta MA, Patel SS, LaBree LD, Walonker F, Rao NA, Chong LP. Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis. Arch Ophthalmol. 1996; 114:815-20. (Pubitemid 26240528)
59. Hatton MP, Duker JS, Reichel E, Morley MG, Puliafito CA. Treatment of relapsed cytomegalovirus retinitis with the sustained-release ganciclovir implant. Retina. 1998;18:50-5. (Pubitemid 28128405)
60. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Arch Ophthalmol. 1996; 114:23-33.
61. Martin BK, Ricks MO, Forman MS, Jabs DA. Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis. Clin Infect Dis. 2007;44:1001-8. (Pubitemid 46452070)
62. Jabs DA, Martin BK, Forman MS, Hubbard L, Dunn JP, Kempen JH, Davis JL, Weinberg DV. Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis. Am J Ophthalmol. 2003;135:26-34. (Pubitemid 36020420)
63. Jabs DA, Martin BK, Ricks MO, Forman MS. Detection of ganciclovir resistance in patients with AIDS and cytomegalovirus retinitis: Correlation of genotypic methods with viral phenotype and clinical outcome. J Infect Dis. 2006;193: 1728-37. (Pubitemid 43839478)
64. Sezgin E, van Natta ML, Ahuja A, Lyon A, Srivastava S, Troyer JL, O'Brien SJ, Jabs DA. Association of host genetic risk factors with the course of cytomegalovirus retinitis in patients infected with human immunodeficiency virus. Am J Ophthalmol. 2011;151:999-1006 e4.
65. Appay V, Fastenackels S, Katlama C, Ait-Mohand H, Schneider L, Guihot A, Keller M, Grubeck-Loebenstein B, Simon A, Lambotte O, Hunt PW, Deeks SG, Costagliola D, Autran B, Sauce D. Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS. 2011; 25:1813-22.
66. Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, Youle M, Robinson MR, Drew WL, Jaffe HS. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med. 1997;126:257-63.
67. Martin DF, Parks DJ, Mellow SD, Ferris FL, Walton RC, Remaley NA, Chew EY, Ashton P, Davis MD, Nussenblatt RB. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol. 1994;112:1531-9. (Pubitemid 24373070)
68. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med. 1999;340:1063-70. (Pubitemid 29162510)